WO2005003325A3 - Inhibition of viral pathogenesis - Google Patents

Inhibition of viral pathogenesis Download PDF

Info

Publication number
WO2005003325A3
WO2005003325A3 PCT/US2004/007537 US2004007537W WO2005003325A3 WO 2005003325 A3 WO2005003325 A3 WO 2005003325A3 US 2004007537 W US2004007537 W US 2004007537W WO 2005003325 A3 WO2005003325 A3 WO 2005003325A3
Authority
WO
WIPO (PCT)
Prior art keywords
infected
inhibition
viral pathogenesis
viral
methods
Prior art date
Application number
PCT/US2004/007537
Other languages
French (fr)
Other versions
WO2005003325A2 (en
Inventor
Ellis L Reinherz
Hailin Yang
Mikyung Kim
Original Assignee
Dana Farber Cancer Inst Inc
Ellis L Reinherz
Hailin Yang
Mikyung Kim
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Inst Inc, Ellis L Reinherz, Hailin Yang, Mikyung Kim filed Critical Dana Farber Cancer Inst Inc
Priority to CA002518716A priority Critical patent/CA2518716A1/en
Priority to JP2006532321A priority patent/JP2007517767A/en
Priority to EP04775837A priority patent/EP1613736A4/en
Publication of WO2005003325A2 publication Critical patent/WO2005003325A2/en
Publication of WO2005003325A3 publication Critical patent/WO2005003325A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The invention features methods of inhibiting activation of cells by viral erb-B ligands and methods of enhancing immune responses in animals (e.g., human subjects) infected, that will be infected, or are at risk of being infected with a virus whose genome contains a nucleic acid sequence encoding a viral erb-B ligand.
PCT/US2004/007537 2003-03-11 2004-03-11 Inhibition of viral pathogenesis WO2005003325A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CA002518716A CA2518716A1 (en) 2003-03-11 2004-03-11 Inhibition of viral pathogenesis
JP2006532321A JP2007517767A (en) 2003-03-11 2004-03-11 Methods for inhibiting viral pathogenicity
EP04775837A EP1613736A4 (en) 2003-03-11 2004-03-11 Inhibition of viral pathogenesis

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US45365103P 2003-03-11 2003-03-11
US60/453,651 2003-03-11
US50927803P 2003-10-07 2003-10-07
US60/509,278 2003-10-07

Publications (2)

Publication Number Publication Date
WO2005003325A2 WO2005003325A2 (en) 2005-01-13
WO2005003325A3 true WO2005003325A3 (en) 2006-03-23

Family

ID=33567313

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/007537 WO2005003325A2 (en) 2003-03-11 2004-03-11 Inhibition of viral pathogenesis

Country Status (4)

Country Link
EP (1) EP1613736A4 (en)
JP (1) JP2007517767A (en)
CA (1) CA2518716A1 (en)
WO (1) WO2005003325A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2538752C (en) 2003-09-19 2011-08-02 Astrazeneca Ab Quinazoline derivatives
WO2005072826A2 (en) * 2004-01-21 2005-08-11 Emory University Compositions and use of tyrosine kinase inhibitors to treat pathogenic infection
CN103058938A (en) * 2011-10-18 2013-04-24 南京大学 4-aniline quinazoline compound substituting cinnamic acid, and preparation method and application thereof
WO2014097762A1 (en) * 2012-12-20 2014-06-26 国立大学法人熊本大学 Antibody to highly pathogenic avian influenza
WO2024049966A2 (en) * 2022-08-31 2024-03-07 Biofactura, Inc. Compositions and methods for the prevention and treatment of orthopoxvirus infections

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001021192A2 (en) * 1999-09-22 2001-03-29 Corixa Corporation Methods for diagnosis and therapy of hematological and virus-associated malignancies

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2376596C (en) * 1999-06-25 2009-10-06 Genentech, Inc. Humanized anti-erbb2 antibodies and treatment with anti-erbb2 antibodies
EP1309348B1 (en) * 2000-02-11 2009-01-07 U.S. Army Medical Research Institute of Infectious Diseases Department of the Army Prophylactic and therapeutic monoclonal antibodies against vaccinia virus antigens

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001021192A2 (en) * 1999-09-22 2001-03-29 Corixa Corporation Methods for diagnosis and therapy of hematological and virus-associated malignancies

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
See also references of EP1613736A4 *
TZAHAR E ET AL: "Pathogenic poxviruses reveal viral strategies to exploit the ErbB signaling network.", EMBO JOURNAL., vol. 17, no. 20, 1998, pages 5948 - 5963, XP002992988 *
WANG X ET AL: "Epidermal growth factor receptor is a cellular receptor for human cytomegalovirus.", NATURE., vol. 424, 24 July 2003 (2003-07-24), pages 456 - 461, XP002995363 *

Also Published As

Publication number Publication date
JP2007517767A (en) 2007-07-05
WO2005003325A2 (en) 2005-01-13
CA2518716A1 (en) 2005-01-13
EP1613736A4 (en) 2007-04-11
EP1613736A2 (en) 2006-01-11

Similar Documents

Publication Publication Date Title
WO2007062656A3 (en) A nucleotide vaccine
AU2003216289A1 (en) Identification of peptides that facilitate uptake and cytoplasmic and/or nuclear transport of proteins, dna and viruses
WO2006044923A3 (en) Yeast-based therapeutic for chronic hepatitis c infection
EP2177535A4 (en) Antibody having inhibitory activity on infection with hepatitis c virus (hcv), and use thereof
WO2008024294A3 (en) Sequences diagnostic for shrimp pathogens
CL2004000799A1 (en) PREVENTION METHOD OF ABORTION IN PRESSED ANIMAL CAUSED BY AN HVB-1 VIRUS, AND / OR BY VDVB OR VDB VIRUS, INFECTION PREVENTION METHOD IN A INFANTING ANIMAL.
FR15C0084I2 (en) VACCINE AGAINST HPV16 AND HPV18 VIRUSES AND AT LEAST ONE OTHER TYPE OF HPV SELECTED AMONG HPV 31, 45 OR 52
WO2005100611A3 (en) Detection of viral nucleic acid and method for reverse transcribing rna
ITMO20040129A1 (en) BLOOD VESSEL FILTER.
WO2004091524A3 (en) Respiratory virus vaccines
WO2005003325A3 (en) Inhibition of viral pathogenesis
WO2002030964A3 (en) Comparative ligand mapping from mhc positive cells
DK1372719T3 (en) Nucleic acid and corresponding protein designated 125P5C8 useful in the treatment and detection of cancer
WO2010014248A3 (en) Antiviral activity of the protein scytovirin and methods of use
DK1689886T3 (en) Molecular marker associated with CMV resistance and its use
IS7775A (en) DNA vaccine, which transcribes at least two unmodified viral viral proteins
WO2009051823A3 (en) Bacterial artificial chromosome containing feline herpes virus type 1 genome and uses thereof
TW200700557A (en) Rt-pcr detection for differential diagnosis field isolates or lapinized vaccine strain of classical swine fever virus (csfv) in samples
WO2007038316A3 (en) Human cytomegalovirus latency promoting genes, related virus variants and methods of use
WO2007019532A3 (en) Peptide aptamers that bind to the rep proteins of ssdna viruses
WO2011041788A3 (en) Turkey viral hepatitis virus and uses thereof
WO2008108660A3 (en) Fish disease detection
WO2004092207A3 (en) Respiratory syncytial virus (rsv) peptides
WO2009054713A8 (en) Detection of epstein-barr virus (ebv) in nasopharyngeal cancer
ATE544856T1 (en) PEPTIDE AND NUCLEOTIDE SEQUENCES OF ANISAKIS SPP. AND THEIR USE

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2518716

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2006532321

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2004775837

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2004775837

Country of ref document: EP